Global & regional health technology assessment · 2026
[Not Available].
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fortunato Agostino, Rumi Filippo, Antonini Debora, Basile Michele, Calosci Elena Maria, D'Ambrosio Floriana, Di Brino Eugenio, Fiore Alessandra, Pappalardo Ciro, Ricciardi Roberto, Scardigno Anna, Sciomenta Ilaria, Calabrò Giovanna Elisa
Аннотация
INTRODUCTION:: Intermittent catheterization is the standard of care for neurogenic bladder dysfunction; however, urinary tract infections (UTIs) remain a major clinical and economic complication in patients with multiple sclerosis (MS) or spinal cord injury (SCI). Micro-hole Zone Technology (MhZT), implemented in the Luja™ catheter, is designed to support bladder emptying.
METHODS:: A static 5-year budget impact model was developed from the perspective of the Italian National Health Service, assuming a stable eligible population and comparing a current scenario without Luja™ with progressive adoption from 5% to 25%. Direct medical costs of catheters and UTI management were included; no discounting was applied. Deterministic scenario analyses explored uncertainty in clinical effect, UTI costs and uptake.
RESULTS:: The eligible population included 64,600 users with SCI and 40,600 with MS. In patients with SCI, Luja™ adoption reduced cumulative 5-year expenditure from € 1,652.9 million to € 1,643.3 million, preventing 28,861 UTIs. In patients with MS, expenditure decreased from € 1,039.2 million to € 1,033.1 million, preventing 18,139 UTIs. Overall, the model estimated approximately 47,000 avoided UTIs and € 15.8 million in related savings.
CONCLUSIONS:: Under the model assumptions, gradual adoption of MhZT may be economically sustainable and potentially cost-saving for the Italian National Health Service. Results are mainly driven by an indirectly estimated reduction in UTIs and should be confirmed using comparative real-world evidence.
METHODS:: A static 5-year budget impact model was developed from the perspective of the Italian National Health Service, assuming a stable eligible population and comparing a current scenario without Luja™ with progressive adoption from 5% to 25%. Direct medical costs of catheters and UTI management were included; no discounting was applied. Deterministic scenario analyses explored uncertainty in clinical effect, UTI costs and uptake.
RESULTS:: The eligible population included 64,600 users with SCI and 40,600 with MS. In patients with SCI, Luja™ adoption reduced cumulative 5-year expenditure from € 1,652.9 million to € 1,643.3 million, preventing 28,861 UTIs. In patients with MS, expenditure decreased from € 1,039.2 million to € 1,033.1 million, preventing 18,139 UTIs. Overall, the model estimated approximately 47,000 avoided UTIs and € 15.8 million in related savings.
CONCLUSIONS:: Under the model assumptions, gradual adoption of MhZT may be economically sustainable and potentially cost-saving for the Italian National Health Service. Results are mainly driven by an indirectly estimated reduction in UTIs and should be confirmed using comparative real-world evidence.